Resources Investment Advisors Inc. increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 27.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,977 shares of the medical research company’s stock after buying an additional 3,269 shares during the period. Resources Investment Advisors Inc.’s holdings in Amgen were worth $2,605,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. FMR LLC raised its stake in Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the last quarter. Vanguard Group Inc. raised its stake in Amgen by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after purchasing an additional 489,720 shares during the last quarter. BlackRock Inc. raised its stake in Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Amgen by 1.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after purchasing an additional 140,117 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the last quarter. Institutional investors and hedge funds own 78.61% of the company’s stock.
AMGN has been the subject of several analyst reports. Vetr downgraded shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price for the company. in a research note on Wednesday, January 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $189.00 target price on shares of Amgen in a research note on Wednesday, January 24th. Piper Jaffray Companies reissued a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Cann reissued a “buy” rating and issued a $205.00 target price on shares of Amgen in a research note on Thursday, November 30th. Finally, Cowen reissued a “buy” rating and issued a $204.00 target price on shares of Amgen in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $191.72.
Amgen, Inc. (NASDAQ:AMGN) opened at $191.10 on Friday. Amgen, Inc. has a one year low of $152.16 and a one year high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The company has a market cap of $137,699.41, a PE ratio of 15.19, a PEG ratio of 2.35 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company posted $2.89 EPS. sell-side analysts forecast that Amgen, Inc. will post 13.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
Amgen announced that its board has initiated a share buyback program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.